Lantheus Holdings, Inc. (LNTH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Lantheus Holdings, Inc. (NASDAQ:LNTH) regarding possible corporate wrongdoing. The firm is encouraging investors who purchased Lantheus securities prior to November 6, 2024, and still hold them, to contact them to learn more and assist with the investigation. The representation is on a contingency fee basis.
Bronstein, Gewirtz & Grossman, LLC Encourages Lantheus Holdings, Inc. (LNTH) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lantheus Holdings, Inc. (NASDAQ:LNTH). The investigation focuses on whether Lantheus and its officers engaged in corporate wrongdoing, targeting investors who bought securities before November 6, 2024, and still hold them. The firm encourages affected shareholders to contact them to assist with the investigation, noting a contingency fee basis for representation.
Trading Systems Reacting to (LNTH) Volatility
This article from Stock Traders Daily discusses the volatility surrounding Lantheus Holdings Inc. (NASDAQ: LNTH), highlighting weak sentiment across all horizons and suggesting a short bias. It details three distinct AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels. The report also mentions an exceptional 68.5:1 risk-reward short setup targeting a 20.0% downside.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Lantheus Holdings, Inc. (NASDAQ:LNTH) for alleged corporate wrongdoing. The firm encourages shareholders who purchased Lantheus securities before November 6, 2024, and still hold them, to join their investigation. Investors can find more information or assist the investigation by visiting the firm's website or contacting their representatives.
11 High Growth Healthcare Stocks to Buy Now
The article highlights Lantheus Holdings, Inc. (NASDAQ:LNTH) as a high-growth healthcare stock, detailing Jefferies' raised price target of $110 with a Buy rating. This rating modification follows a conference and meeting with the company, leading to updated PSMA PET model and pricing assumptions. The FDA also extended its review of LNTH-2501 by three months, though not due to efficacy or safety concerns.
11 High Growth Healthcare Stocks to Buy Now
This article, part of a larger list, highlights Lantheus Holdings, Inc. (NASDAQ:LNTH) as a high-growth healthcare stock to consider. It details a recent price target increase by Jefferies to $110, reiterating a Buy rating based on updated PSMA PET model assumptions and the PYLARIFY TruVu commercial rollout projection. The article also notes the FDA's three-month extension for LNTH-2501's review, clarifying it's unrelated to efficacy or safety, and describes Lantheus's role in diagnostic imaging and nuclear medicine.
Assenagon Asset Management S.A. Trims Position in Lantheus Holdings, Inc. $LNTH
Assenagon Asset Management S.A. significantly reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 94.4% in the fourth quarter, selling over 1.2 million shares. Despite this, Lantheus reported strong financial results, surpassing quarterly expectations for EPS and revenue, and provided positive FY2026 guidance. Analyst sentiment remains largely positive with a "Moderate Buy" rating and an average price target of $86.14.
Lantheus (NASDAQ:LNTH) Rating Increased to Strong-Buy at Wall Street Zen
Wall Street Zen has upgraded Lantheus (NASDAQ:LNTH) from a "buy" to a "strong-buy" rating. This upgrade comes despite the company beating quarterly expectations with $1.67 EPS and $406.8M revenue, though its FY 2026 EPS guidance is lower than analyst forecasts. Lantheus currently holds a consensus "Moderate Buy" rating among analysts with an average target price of $86.14.
Vanguard disaggregates holdings; Vanguard subsidiaries to report LNTH positions (LNTH)
The Vanguard Group has filed an Amendment No. 8 to Schedule 13G/A, reporting zero beneficial ownership of Lantheus Holdings Inc. (LNTH) common stock. This change is due to an internal realignment on January 12, 2026, which disaggregates holdings, meaning Vanguard subsidiaries will now report their positions separately. The filing states that Vanguard itself now beneficially owns 0% of LNTH's class.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lantheus Holdings, Inc. (LNTH) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate misconduct by Lantheus Holdings, Inc. (LNTH) and certain officers/directors. The firm is encouraging shareholders who purchased Lantheus securities before November 6, 2024, and still hold them, to contact them to assist with the investigation. The firm operates on a contingency fee basis for class actions, meaning investors will only incur costs if the firm is successful in its recovery efforts.
William Blair, Jefferies Maintain LNTH Lantheus Holdings March 2026: Outperform Buy
William Blair and Jefferies both maintained their ratings on Lantheus Holdings (LNTH) on March 17, 2026, with William Blair reiterating Outperform and Jefferies reaffirming Buy while raising its price target to $110. These actions signal continued analyst confidence despite a recent -7.72% stock movement due to regulatory timing. Investors are advised to consider approval timing and execution risk, while Meyka AI rates LNTH with an 'A' grade.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Lantheus Holdings, Inc. (NASDAQ:LNTH). The firm encourages investors who purchased Lantheus securities before November 6, 2024, and still hold them, to join the investigation. The inquiry aims to determine if the company and its officers engaged in misconduct.
CWA Asset Management Group LLC Makes New $1.67 Million Investment in Lantheus Holdings, Inc. $LNTH
CWA Asset Management Group LLC has made a new investment of $1.67 million in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, acquiring 25,096 shares. Lantheus exceeded quarterly earnings and revenue expectations, reporting $1.67 EPS against an estimated $1.17, and has provided strong FY2026 guidance. Analysts maintain a "Moderate Buy" rating for the stock, with a consensus price target of $86.14.
Lantheus Holdings, Inc. (LNTH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Lantheus Holdings, Inc. (LNTH) for alleged corporate wrongdoing. Shareholders who purchased Lantheus securities prior to November 6, 2024, and still hold them, are encouraged to contact the law firm to learn more and assist with the investigation. The firm operates on a contingency fee basis, meaning there is no cost to investors unless they are successful.
Is It Time To Revisit Lantheus Holdings (LNTH) After Its Recent Share Price Swings?
This article analyzes Lantheus Holdings (LNTH) current valuation following recent share price fluctuations. Using DCF analysis and P/E ratio comparison, the stock appears undervalued, with an estimated intrinsic value of $168.16 per share compared to a recent price of $76.43. The article also introduces "Narratives" for investors to tailor their own valuation models based on bullish or bearish assumptions about the company's future growth and market conditions.
Class Action Announcement for Lantheus Holdings, Inc. Investors
A class action lawsuit has been filed against Lantheus Holdings, Inc. alleging securities fraud. The lawsuit claims Lantheus made misleading statements about PYLARIFY's competitive position and failed to disclose how a price increase created opportunities for competitive pricing, risking the product's growth. Investors who purchased Lantheus securities between February 26, 2025, and August 5, 2025, have until November 10, 2025, to seek lead plaintiff status.
Lantheus says FDA extended review period for radioactive diagnostic kit
Lantheus Holdings announced that the U.S. Food and Drug Administration (FDA) has extended its review period for the company's New Drug Application for Pylarify. The diagnostic kit is a radioactive agent aimed at detecting prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. The extension by three months is to allow for a full review of information submitted by Lantheus in response to FDA requests.
[ARS] Lantheus Holdings, Inc. SEC Filing
This article announces an SEC filing for Lantheus Holdings, Inc. (LNTH), specifically an ARS form. The filing was accepted on March 20, 2026, and is assessed with low impact and neutral sentiment. The article also provides recent news and other SEC filings related to Lantheus.
Lantheus Holdings Inc (LNTH) Trading Down 3.37% on Mar 19
Lantheus Holdings Inc (LNTH) saw its shares decline by 3.37% on March 19, trading at $77.56, which is 28.79% below its 52-week high and 64.14% above its 52-week low. Wall Street analysts have an average target price of $88.62 for LNTH, suggesting a 14.26% upside, and the stock holds an "Outperform" status. GuruFocus estimates the GF Value at $93.35, indicating a 20.37% upside.
How Lantheus Holdings Inc. (LNTH) Affects Rotational Strategy Timing
This article analyzes various trading strategies for Lantheus Holdings Inc. (LNTH) based on AI-generated signals. It identifies near-term weak sentiment, mid-term strength, and a broader long-term weak bias, noting elevated downside risk. The analysis provides specific entry and exit points for position trading, momentum breakout, and risk hedging strategies.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Lantheus Holdings, Inc. (LNTH) on behalf of investors who purchased securities prior to November 6, 2024, and still hold them. The investigation focuses on whether Lantheus and its officers/directors engaged in corporate wrongdoing. The firm encourages affected investors to contact them for more information and to assist in the investigation without any cost.
A Look At Lantheus Holdings (LNTH) Valuation After FDA Approval Of PYLARIFY TruVu
Lantheus Holdings (LNTH) is under scrutiny after the FDA approved PYLARIFY TruVu, a new prostate cancer imaging agent, which could boost manufacturing efficiency and product reach. Despite recent share price gains, the stock has experienced a long-term decline. Simply Wall St assesses Lantheus as modestly undervalued at $80.24, with a fair value of $84.62, based on strong fundamentals and strategic acquisitions in the radiopharmaceutical and neuroimaging markets.
Lantheus says FDA extended review period for radioactive diagnostic kit
The FDA has extended the review period for Lantheus Holdings' radioactive diagnostic kit, LNTH-2501, by three months. The original target action date was March 29, 2026, and the company made the announcement today following the FDA's decision.
Lantheus says FDA pushed deadline for reviewing its tumor diagnostic kit application
Lantheus has announced that the FDA has extended the review period for its tumor diagnostic kit application. The company did not specify the new deadline or the reasons for the extension in the provided content. This indicates a delay in the regulatory approval process for the diagnostic kit.
Lantheus stock holds Outperform at William Blair after FDA delay
William Blair maintained an Outperform rating on Lantheus Holdings despite the FDA extending the review period for its drug candidate Octevy by three months. The firm expects the commercial launch of Octevy in Q3 this year, projecting sales of $2 million and $5 million for Q3 and Q4, respectively. This extension is likely due to the FDA classifying an additional information submission as a major amendment.
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
Lantheus Holdings, Inc. announced a three-month extension of the PDUFA date for its New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide) to June 29, 2026. This extension was granted by the FDA to allow additional time to review manufacturing-related information and is not due to concerns about the drug's efficacy or safety. LNTH-2501 is a diagnostic imaging kit for detecting somatostatin receptor-positive neuroendocrine tumors (NETs) in adult and pediatric patients.
Lantheus Says FDA Pushed Deadline For Reviewing Its Tumor Diagnostic Kit Application
Lantheus announced that the FDA has extended the review period for its tumor diagnostic kit, LNTH-2501, by three months, pushing the decision deadline to June 29. The extension is due to the agency needing more time to review manufacturing information, not issues with efficacy or safety. Despite this, some retail sentiment on Stocktwits was bearish, though analyst ratings remain largely positive.
US FDA extends review of Lantheus' diagnostic imaging kit by three months
The U.S. health regulator has extended its review of Lantheus Holdings' diagnostic imaging kit, LNTH-2501, by three months to gather more manufacturing-related information. This delay is not due to concerns about efficacy or safety data, and the FDA is expected to make a decision on approval by June 29. LNTH-2501 is designed to help detect neuroendocrine tumors using PET scans.
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
Lantheus Holdings, Inc. announced a three-month extension of the PDUFA date for its LNTH-2501 (Gallium 68 edotreotide) by the U.S. Food and Drug Administration (FDA). The new target date is June 29, 2026, to allow the FDA additional time to review manufacturing-related information. This extension is a standard review process and is not related to the efficacy or safety data of LNTH-2501, which is a diagnostic kit for imaging neuroendocrine tumors.
Jefferies Maintains Buy on Lantheus Holdings (LNTH) Mar 17 2026
Jefferies has reiterated its "Buy" rating on Lantheus Holdings (LNTH) and increased the price target to $110, signaling continued confidence in the company's imaging and diagnostic portfolio. This action suggests Jefferies anticipates stronger future earnings or margin expansion, though the immediate market reaction to the announcement was muted. Meyka AI also rates LNTH with an A grade, indicating a constructive long-term outlook for investors, who should monitor upcoming quarterly results and operational updates.
Bronstein, Gewirtz & Grossman, LLC Encourages Lantheus Holdings, Inc. (LNTH) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lantheus Holdings, Inc. (NASDAQ:LNTH) securities. The firm encourages stockholders who purchased shares before November 6, 2024, and still hold them, to contact them regarding a securities investigation into potential corporate wrongdoing by Lantheus and its officers/directors. The firm operates on a contingency fee basis for class actions, aiming to restore investor capital and ensure corporate accountability.
Lantheus Holdings Inc Stock (ISIN: US5156731020) Faces Pressure as Farallon Sells 3.245 Million Shar
Lantheus Holdings Inc (LNTH) is experiencing selling pressure after Farallon Capital Management LLC divested 3.245 million shares, despite the company reaffirming strong FY 2026 EPS guidance of $5.00-$5.25 and analysts projecting $6.01. The company, a leader in radiopharmaceuticals, maintains solid fundamentals driven by its precision diagnostics business, particularly PYLARIFY, and a promising therapeutic pipeline. European investors consider LNTH a growth-oriented holding, balancing institutional selling with long-term optimism in the radiopharma sector.
Farallon Capital Management LLC Sells 3,245,000 Shares of Lantheus Holdings, Inc. $LNTH
Farallon Capital Management LLC significantly reduced its stake in Lantheus Holdings, Inc. by selling 3,245,000 shares, a 48.3% decrease, holding 3,477,227 shares valued at $178 million. Other hedge funds like Assenagon Asset Management S.A. and Polaris Capital Management LLC established new positions in Lantheus. Lantheus reported strong Q4 earnings, beating analyst estimates, and has received a "Moderate Buy" rating from analysts with an average target price of $82.17.
Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Recommendation of "Moderate Buy" by Analysts
Lantheus Holdings, Inc. (NASDAQ:LNTH) has received a "Moderate Buy" consensus rating from ten analysts, with an average 12-month price target of $82.17. The company recently surpassed Q4 earnings and revenue estimates and provided positive FY2026 guidance. Institutional investors and hedge funds hold a significant portion of the stock.
Portolan Capital Management LLC Purchases 42,731 Shares of Lantheus Holdings, Inc. $LNTH
Portolan Capital Management LLC increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 16.8%, acquiring an additional 42,731 shares to bring its total holdings to 297,208 shares, valued at approximately $15.24 million. This comes as Lantheus reported strong quarterly earnings, beating expectations with $1.67 EPS and $406.8 million in revenue, and issued optimistic FY2026 guidance. Multiple analysts have upgraded their ratings and price targets for Lantheus, leading to a consensus "Moderate Buy" rating with an average target price of $82.17.
Lantheus Secures Two FDA Milestones in Four Days: Lutathera Radioequivalent and PSMA PET Upgrade
Lantheus Holdings, Inc. recently achieved two significant FDA milestones within four days in early March 2026, advancing both radiopharmaceutical therapy and precision diagnostics. The company received tentative FDA approval for PNT2003, making it the first radioequivalent to LUTATHERA® for GEP-NETs, and concurrently approved PYLARIFY TruVu™, an enhanced formulation of its leading PSMA PET imaging agent for prostate cancer. These approvals underscore Lantheus' strategy to integrate cancer diagnostics ("Find") with targeted radiotherapeutic treatment ("Fight and Follow").
Lantheus Holdings (LNTH) Is Up 5.4% After New PYLARIFY TruVu And LUTATHERA Approvals - Has The Bull Case Changed?
Lantheus Holdings received FDA approval for PYLARIFY TruVu and tentative approval for a LUTATHERA radioequivalent, leading to a 5.4% stock increase. These approvals aim to strengthen Lantheus's position in prostate and neuroendocrine tumor imaging, improve manufacturing efficiency, and diversify its radiopharmaceutical portfolio. However, the company still faces near-term risks related to pricing pressure, reimbursement, and potential PYLARIFY softness, with the success of TruVu's launch being a key short-term catalyst.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against Lantheus Holdings, Inc. (LNTH) and its officers/directors for corporate wrongdoing. The firm is encouraging stockholders who purchased Lantheus securities before November 6, 2024, and still hold them, to learn more and assist in the investigation. The investigation aims to restore investor capital and ensure corporate accountability.
WINTON GROUP Ltd Grows Position in Lantheus Holdings, Inc. $LNTH
WINTON GROUP Ltd significantly increased its stake in Lantheus Holdings, Inc. by 350.8% in Q3, now holding 65,125 shares valued at $3.34 million. This move is part of broader institutional ownership, with 99.06% of Lantheus stock held by such investors. Lantheus recently outperformed earnings estimates, reporting $1.67 EPS and $406.8 million in revenue, leading to a "Moderate Buy" consensus from analysts with an average price target of $82.17.
A Look At Lantheus Holdings (LNTH) Valuation After FDA Approval Of PYLARIFY TruVu
Lantheus Holdings (LNTH) recently saw its shares rise following FDA approval of PYLARIFY TruVu, a new prostate cancer imaging agent designed for wider access. Despite a 27.27% decline over the past year, recent short-term gains suggest improving momentum. The company is considered 5.4% undervalued, with new product launches expected to diversify revenue and expand earnings, though concentration and pricing risks for PYLARIFY remain key watchpoints.
2026-03-08 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lantheus Holdings, Inc. (LNTH) And Encourages Investors to Reach Out | NDAQ:LNTH | Press Release
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into Lantheus Holdings, Inc. (LNTH) due to potential corporate wrongdoing. The firm is encouraging investors who purchased Lantheus securities before November 6, 2024, and still hold them, to contact them for more information and to assist in the investigation. The firm operates on a contingency fee basis, meaning investors will not incur costs unless the firm is successful in recovering funds.
Teachers Retirement System of The State of Kentucky Reduces Stake in Lantheus Holdings, Inc. $LNTH
The Teachers Retirement System of The State of Kentucky significantly reduced its stake in Lantheus Holdings, Inc. by 49% during the third quarter of 2026, selling 19,494 shares and retaining 20,321 shares valued at over $1 million. Despite this reduction, several other major institutions increased or initiated positions in LNTH, leading to institutional ownership remaining near 99.06%. The company also reported strong quarterly earnings, exceeding analyst estimates, and provided positive FY2026 guidance, with a consensus "Moderate Buy" rating and an $82.17 price target.
American Century Companies Inc. Sells 341,642 Shares of Lantheus Holdings, Inc. $LNTH
American Century Companies Inc. reduced its stake in Lantheus Holdings Inc. by 32.1% in the third quarter, selling over 341,000 shares and now owning 1.09% of the company valued at $37 million. Lantheus (NASDAQ:LNTH) reported strong quarterly earnings, beating revenue and EPS estimates, and has an average analyst rating of "Moderate Buy" with a target price of $82.17. Several institutional investors also adjusted their positions in the medical equipment provider during recent quarters.
Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection
Lantheus Holdings, Inc. announced that the FDA has approved PYLARIFY TruVu (piflufolastat F 18) injection, a new formulation of its PSMA PET imaging agent for prostate cancer. This new formulation maintains the diagnostic performance of PYLARIFY while offering potential for larger batches and greater patient availability by enhancing product stability at higher radioactive concentrations. PYLARIFY TruVu is expected to launch in Q4 2026 with a phased geographic rollout, aiming to improve supply flexibility and manufacturing efficiency for this critical diagnostic tool.
FDA approves Lantheus’ PYLARIFY TruVu for prostate cancer imaging By Investing.com
Lantheus Holdings Inc. announced FDA approval for PYLARIFY TruVu, a new formulation of their prostate cancer imaging agent, indicated for PSMA-positive lesions in men with suspected metastasis or recurrence. This new formulation aims to improve manufacturing efficiency and distribution, with commercial availability expected in Q4 2026. Despite positive developments, including tentative FDA approval for a generic cancer drug, analyst opinions on Lantheus's stock performance are mixed.
Why Is LNTH Stock Up After Hours?
Lantheus (LNTH) stock rose after hours following the FDA approval of its PYLARIFY TruVu injection, a new formulation for imaging prostate cancer lesions. This new version maintains diagnostic properties while offering more efficient manufacturing and distribution, aiming to improve supply flexibility. It is expected to be commercially available in the fourth quarter of 2026.
US FDA approves Lantheus’ new prostate cancer imaging formulation
The U.S. FDA has approved Pylarify TruVu, a new formulation of Lantheus Holdings' prostate cancer imaging agent, designed to increase production capacity and improve access to PSMA PET scans. This new version maintains diagnostic performance but allows for larger batches and more efficient distribution. Analysts view this approval as a significant catalyst for Lantheus, anticipating a re-acceleration in revenue and profit from the second half of 2026.
FDA OKs new PYLARIFY TruVu scan to expand prostate cancer imaging
Lantheus (NASDAQ: LNTH) has received FDA approval for PYLARIFY TruVu™ (piflufolastat F 18) injection, a new formulation of its PSMA PET imaging agent for prostate cancer. This approval, based on OSPREY and CONDOR study data, aims to enable larger batch production and wider patient access for the diagnostic tool. The commercial launch of PYLARIFY TruVu is expected in the fourth quarter of 2026, with a phased geographic rollout.
Lantheus Announces FDA Approval of PYLARIFY TruVu™, a New Formulation of Its PSMA PET Imaging Agent to Enhance Patient Access and Supply Capacity
Lantheus Holdings, Inc. announced FDA approval for PYLARIFY TruVu, a new formulation of its PSMA PET imaging agent for prostate cancer diagnostics, planned for Q4 2026 launch. This new formulation aims to enhance patient access and supply capacity through larger batch sizes and improved stability, while maintaining the diagnostic performance and safety profile of the original PYLARIFY. The company anticipates a phased geographic rollout to ensure a smooth transition for customers.
Elo Mutual Pension Insurance Co Acquires New Stake in Lantheus Holdings, Inc. $LNTH
Elo Mutual Pension Insurance Co. has acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the third quarter, purchasing 18,370 shares valued at approximately $942,000. Institutional investors now own about 99.06% of the company. Lantheus exceeded Q3 earnings expectations, reporting an EPS of $1.67 against an expected $1.17, and revenue of $406.8M against $367.0M expected, with strong analyst sentiment for the stock.
